Navigation Links
AACR, NCI and EORTC to host Molecular Targets and Cancer Therapeutics International Conference
Date:11/9/2009

PHILADELPHIA Scientists and industry leaders from around the world will gather in Boston Nov. 14-19, 2009, for the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference, which will feature groundbreaking information on important cancer therapies in development.

"Cancer is a complex disease and to treat it effectively we need a greater understanding of the activity that takes place at the molecular level," said Lewis Cantley, Ph.D., director of the cancer center at Beth Israel Deaconess Medical Center and one of the scientific committee chairpersons of the conference. "The research presented at this conference will bring us closer to that understanding."

Experts from the world's leading cancer centers and pharmaceutical companies will discuss innovations in drug development, target selection and the impact of new discoveries in molecular and cellular biology.

Understanding the pathways and mechanisms that cause cancer and regulate the biological behavior of tumor cells has already led to the development of numerous new agents. This conference, now in its second decade, has been organized to reflect the many recent advances in the early development of promising new compounds.

During the conference, the American Association for Cancer Research will host several press briefings: "Drugs in the Pipeline," "Emerging Therapies in Pancreatic Cancer" and "Markers of Prognosis."


'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Page: 1

Related biology news :

1. AACR, NCI and EORTC to host molecular targets and cancer therapeutics conference
2. AACR, BCRF award inaugural grants in translational breast cancer research
3. Media invitation: 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics
4. Trembling hands and molecular handshakes
5. NHLBI awards $11 million for molecular roadmap to chronic lung diseases
6. Cements basic molecular structure finally decoded
7. Powerful new molecular GPS helps probe aging and disease processes
8. Think zinc: Molecular sensor could reveal zincs role in diseases
9. Stimulus funding helps K-State bring undergrads to prairie for ecology, molecular biology research
10. Pitt study finds molecular link between insulin resistance and inflammation
11. Stem cell research: From molecular physiology to therapeutic applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
Breaking Biology News(10 mins):
(Date:5/19/2016)... ... May 19, 2016 , ... KCAS Bioanalytical and Biomarker Services, ... Director, Large Molecule & Biomarker Bioanalysis. , Dr. Siddiqui has more than 15 ... for preclinical and clinical safety programs. “We’ve seen significant demand for, and we ...
(Date:5/18/2016)... 2016 The Biotech industry continues to ... that there are no opportunities ahead. Today, ActiveWallSt.com has on ... THLD ), Seattle Genetics Inc. (NASDAQ: SGEN ... Corp. (NASDAQ: OPHT ). Sign up now to ... http://www.activewallst.com/ Threshold Pharmaceuticals Inc.,s shares gained ...
(Date:5/17/2016)... -- Haselmeier announces the launch by Merck ... EMA, the European Medicines Agency. Originally launched in 2011 ... new pen version includes enhancements to further improve the ... patients during use. Its enhanced design has ... with a larger display window that improves the readability ...
(Date:5/17/2016)... BASEL, Switzerland , May 17, 2016 /PRNewswire/ ... sciences company located in Basel, Switzerland ... an investigational oral inhibitor of P38 mitogen-activated protein ... ) , Strekin will build the ... Pamapimod in indications in which MAP Kinases play ...
Breaking Biology Technology: